Trial Profile
A study to characterize the acute electrophysiologic properties, safety and tolerability of GAP-486 [rotigaptide]
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2006
Price :
$35
*
At a glance
- Drugs Rotigaptide (Primary)
- Indications Arrhythmias
- Focus Therapeutic Use
- 07 Nov 2006 Status change
- 12 Oct 2006 Status change
- 20 Nov 2005 New trial record.